Indo US Bio-Tech Ltd (INDOUS) share price, results

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	15.81	22.11	15.77	24.72	22.17	23.56	33.38	30.77	30.85	22.80	26.02	32.99
Expenses	13.21	17.88	14.79	21.03	17.05	18.02	28.80	25.30	26.69	18.65	22.79	29.02
Operating Profit	2.60	4.23	0.98	3.69	5.12	5.54	4.58	5.47	4.16	4.15	3.23	3.97
OPM %	16.45%	19.13%	6.21%	14.93%	23.09%	23.51%	13.72%	17.78%	13.48%	18.20%	12.41%	12.03%
Other Income	0.00	0.08	0.21	0.03	0.02	0.02	0.12	0.00	0.03	0.01	0.02	0.12
Interest	0.41	0.37	0.36	0.33	0.52	0.38	0.26	0.45	0.42	0.77	0.60	0.74
Depreciation	0.21	0.19	0.20	0.20	0.18	0.16	0.56	0.20	0.21	0.22	0.27	0.27
Profit before tax	1.98	3.75	0.63	3.19	4.44	5.02	3.88	4.82	3.56	3.17	2.38	3.08
Tax %	15.66%	1.87%	17.46%	0.63%	2.03%	-0.80%	4.90%	2.49%	3.09%	5.36%	17.23%	1.30%
Net Profit	1.67	3.68	0.52	3.17	4.36	5.05	3.68	4.70	3.45	3.00	1.97	3.04
EPS in Rs	0.83	1.84	0.26	1.58	2.17	2.52	1.84	2.34	1.72	1.50	0.98	1.52

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	19	24	29	35	40	39	49	61	73	104	110	113
Expenses	19	23	27	32	36	34	42	51	62	85	93	97
Operating Profit	0	1	3	3	4	6	7	9	11	19	17	16
OPM %	2.6%	5%	9%	10%	10%	14%	14%	15%	15%	18%	15%	14%
Other Income	0	0	0	0	-0	0	0	0	0	0	0	0
Interest	0	1	1	0	1	1	1	1	2	1	2	3
Depreciation	0	0	0	0	0	0	0	1	1	1	1	1
Profit before tax	0	1	2	3	3	4	5	7	9	17	14	12
Tax %	-50%	25%	29%	26%	12%	-23%	5%	2%	6%	2%	6%
Net Profit	0	0	1	2	3	5	5	7	8	16	13	11
EPS in Rs	0.80	0.89	1.41	1.44	1.74	3.52	2.86	3.60	4.11	8.11	6.54	5.72
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

	10 Years	5 Years	3 Years	TTM	1 Year	Last Year
Compounded Sales Growth	19%	23%	22%	3%
Compounded Profit Growth	43%	21%	22%	-36%
Stock Price CAGR	%	21%	-32%		-43%
Return on Equity	18%	17%	18%			15%

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	1	1	1	3	5	6	6	9	10	20	20	20
Reserves	1	2	2	2	9	10	15	30	44	43	58	72
Borrowings	2	5	5	7	6	9	11	12	12	14	15	37
Other Liabilities	3	6	4	6	4	10	11	4	3	7	4	4
Total Liabilities	8	14	13	17	24	35	44	56	69	84	98	133
Fixed Assets	1	1	1	2	1	1	2	6	7	7	10	11
CWIP	0	0	0	0	1	1	2	2	1	4	0	0
Investments	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	7	13	11	16	21	32	39	48	61	74	88	121
Total Assets	8	14	13	17	24	35	44	56	69	84	98	133

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	0	-1	-3	-1	0	3	1	2	1	-13
Cash from Investing Activity	-0	0	-3	-1	-2	-5	-7	-3	-1	-2
Cash from Financing Activity	0	1	6	2	1	2	6	1	-1	20
Net Cash Flow	-0	0	0	0	-0	-0	0	1	-1	6
Free Cash Flow	-0	-1	-4	-1	-2	-1	-1	-0	1	-15
CFO/OP	11%	-16%	-92%	-20%	6%	47%	9%	23%	9%	-71%

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	25	107	76	112	94	193	229	152	148	95	53	45
Inventory Days	91	118	92	98	176	751
Days Payable	57	115	64	71	34	667
Cash Conversion Cycle	59	110	104	138	236	276	229	152	148	95	53	45
Working Capital Days	66	33	34	59	129	137	186	257	285	266	247	248
ROCE %	14%	7%	14%	28%	20%	17%	18%	16%	15%	14%	21%	14%

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	70.17%	70.17%	70.18%	70.18%	70.18%	70.18%	70.18%	70.18%	70.18%	70.18%	68.29%	68.29%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.18%	0.01%
Public	29.83%	29.83%	29.83%	29.82%	29.83%	29.82%	29.83%	29.83%	29.83%	29.83%	31.53%	31.70%
No. of Shareholders	318	1,227	1,166	1,133	971	2,828	2,780	3,112	4,130	4,738	4,531	4,690

Fundamentals

Market Cap₹ 156 Cr.

Current Price₹ 77.4

Stock P/E13.6

Book Value₹ 46.2

ROCE14.5 %

ROE15.3 %

Dividend Yield0.32 %

Face Value₹ 10.0

Compounded Sales Growth (TTM)3%

Compounded Profit Growth (TTM)-36%

Standalone figures.

Valuation

Market capRs 154 Cr

Enterprise valueRs 185 Cr

P/E (TTM)13.48x

Price to book1.67x

Price to sales1.37x

EV / EBITDA11.81x

EV / EBIT12.59x

EV / sales1.65x

Earnings yield7.42%

P/E, 3-year average36.19x

P/B, 3-year average5.45x

P/E, 5-year average23.25x

P/B, 5-year average3.41x

Profitability

Operating margin (excl. other income)15.40%

Operating margin (incl. other income)15.45%

EBITDA margin13.93%

Pre-tax margin10.82%

Net profit margin10.17%

Net margin, latest quarter9.21%

ROE15.34%

ROCE14.50%

ROA11.36%

ROE, 3-year average17.48%

ROCE, 3-year average16.68%

ROA, 3-year average13.31%

ROE, 5-year average17.06%

ROCE, 5-year average16.10%

ROA, 5-year average12.41%

ROIC (approx.)11.24%

Tax rate5.75%

Other income / net worth0.05%

Growth

Sales growth (latest year)6.36%

Profit growth (latest year)-19.36%

Sales CAGR, 3 years21.99%

Sales CAGR, 5 years22.91%

Profit CAGR, 3 years21.92%

Profit CAGR, 5 years20.80%

Sales growth QoQ26.79%

Profit growth QoQ54.31%

Sales growth YoY (latest quarter)7.21%

Profit growth YoY (latest quarter)-35.32%

Per share

EPS (TTM)Rs 5.69

EPS (latest quarter)Rs 1.51

EPS, 3-year averageRs 6.11

EPS, 5-year averageRs 6.29

Book value per shareRs 45.98

Sales per shareRs 55.98

Cash flow per shareRs -6.25

Free cash flow per shareRs -7.45

Efficiency

Asset turnover0.83x

Fixed asset turnover9.84x

Inventory turnover0.02x

Inventory days18830 days

Debtor days45 days

Debtors turnover8.03x

Creditor days667 days

Cash conversion cycle45 days

Working capital days248 days

Leverage

Total debtRs 37 Cr

Cash and bankRs 6 Cr

Net debtRs 31 Cr

Debt to equity0.40x

Net debt / EBITDA1.97x

Interest coverage5.82x

Owners' fund to total sources69.52%

Debt to assets27.82%

Cash flow

Cash from Operating Activity (latest year)Rs -13 Cr

Cash from Investing Activity (latest year)Rs -2 Cr

Cash from Financing Activity (latest year)Rs 20 Cr

Net Cash Flow (latest year)Rs 6 Cr

Free cash flow (latest year)Rs -15 Cr

FCFE (approx.: FCF + change in debt)Rs 7 Cr

Cash from ops / profit, 5 years-0.12x

Statement figures

Net sales (TTM)Rs 113 Cr

Net sales (latest year)Rs 110 Cr

Sales (latest quarter)Rs 33 Cr

Operating profit excl. other income (latest year)Rs 17 Cr

Operating profit (latest quarter)Rs 4 Cr

Other income (TTM)Rs 0 Cr

EBITDA (TTM)Rs 16 Cr

PBDT (TTM)Rs 13 Cr

Profit before tax (TTM)Rs 12 Cr

Tax (latest year)Rs 1 Cr

Net profit (TTM)Rs 11 Cr

Net profit (latest year)Rs 13 Cr

Net profit (latest quarter)Rs 3 Cr

Depreciation (TTM)Rs 1 Cr

Depreciation (latest quarter)Rs 0 Cr

Interest (TTM)Rs 3 Cr

Cost of goods sold (latest year)Rs 2 Cr

Total expenditure (latest year)Rs 93 Cr

Total income (latest year)Rs 110 Cr

Share capitalRs 20 Cr

ReservesRs 72 Cr

Shareholders' fundsRs 93 Cr

Total assetsRs 133 Cr

Net blockRs 11 Cr

Capital work in progressRs 0 Cr

ReceivablesRs 14 Cr

InventoryRs 99 Cr

Other liabilitiesRs 4 Cr

Shares outstanding (crore)2.01

Ownership

Promoter holding68.29% (-1.89 in a year)

Computed by MarketFriction from the standalone statements. Returns use average balances.

P/E 13.4 is at the 15th percentile of its own 8.5-year range (median 22.8, low 6.6, high 93.2).

P/B 1.66 is at the 2th percentile (median 4.19).

Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.

Period	INDOUS	Nifty 50	Difference
1 week	-1.7%	-2.8%	+1.1 pts
1 month	-3.0%	-6.8%	+3.8 pts
3 months	-13.9%	-7.6%	-6.3 pts
6 months	-21.9%	+0.4%	-22.3 pts
1 year	-45.2%	-9.9%	-35.3 pts
3 years	-68.6%	+14.2%	-82.8 pts
5 years	+142.7%	+27.9%	+114.8 pts

Red flags

F-score 2 of 8

explain	Weak cash conversion Cash from operations was -24% of net profit over the last 3 years
explain	High accruals Profit exceeded operating cash by 19% of total assets in 2026
explain	Debt up, profit down Borrowings up 150% while net profit fell in 2026
look	Inventory outrunning sales Inventory grew 40% vs sales +6% in 2026
look	Auditor change Auditor change 2026-06-17: Indo Us Biotech Limited has informed the Exchange regarding Change in Auditors of the company.

Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026

Sales ₹33 Cr +7.2% vs Jun 2025. Net profit ₹3 Cr -35.3%.

Against our estimate for Jun 2026: sales +22.7%, profit -7.1% in line. Our estimate for Sep 2026: sales Rs 29 Cr, profit Rs 3 Cr (how).

Activity

Compare

Company	Mcap (Cr)	P/E	ROCE
L T Foods Ltd	13,987	21.8	17.6 %
KRBL Ltd	8,840	11.7	15.2 %
Gujarat Ambuja Exports Ltd	7,419	17.7	12.5 %
TruAlt Bioenergy Ltd	3,940	25.2	10.4 %
Kaveri Seed Company Ltd	3,801	15.2	15.8 %
Sanstar Ltd	2,122	48.2	5.69 %
Amir Chand Jagdish Kumar (Exports) Ltd	2,091	16.9	15.7 %
GRM Overseas Ltd	1,632	21.3	14.0 %
AVT Natural Products Ltd	1,403	16.7	14.2 %
Chamanlal Setia Exports Ltd	1,401	11.2	18.2 %
Gulshan Polyols Ltd	1,027	6.96	18.6 %
Regaal Resources Ltd	909	14.0	12.0 %
Bombay Super Hybrid Seeds Ltd	893	31.1	16.0 %
True Green Bio Energy Ltd	622	11.6	13.8 %
Mangalam Global Enterprise Ltd	533	14.4	17.0 %

No bulk or block deals on record.

Ex-date	Action	Factor
2024-12-03	Interim Dividend - Rs 0.25 Per Share

Date	Type	What it says
2026-10-02	Shareholder meeting	Voting results.
2026-09-30	Shareholder meeting	Proceedings of Annual General Meeting held on September 30, 2026
2026-09-05	Shareholder meeting	Intimation of Book Closure for the purpose of 22nd AGM pursuant to Regulation 42 of SEBI (LODR)
2026-09-05	Shareholder meeting	Notice of Annual General Meeting to be held on September 30, 2026
2026-09-05	Board meeting outcome	Outcome of Board Meeting held on September 05, 2026.
2026-08-12	Integrated Filing- Financial	Submission of Standalone Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
2026-08-12	Board meeting outcome	Indo Us Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-05	Shareholder meeting	Proceedings of Postal Ballot
2026-08-05	Shareholder meeting	Voting results.
2026-07-21	Structural Digital Database	COMPLIANCE CERTIFICATE FOR THE QUARTER ENDED ON 30-06-2026
2026-07-15	General Updates	Revised Outcome of the Board Meeting held on 10 July 2026. Reconstitution of Committees.Committee Composition approved in the Outcome of Board Meetin...
2026-07-15	General Updates	Revised: Additional Details Required For Corporate Announcement Filed Under Regulation 30 Of SEBI (LODR) Regulations, 2015. Ref.: Mail From Query.Lodr...
2026-07-10	Board meeting outcome	Outcome of Board Meeting held on July 10, 2026 Change in Composition of Committees of the Board.
2026-07-06	Disclosure under SEBI Takeov	Jagdishkumar Devjibhai Ajudiya has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India...
2026-07-04	Shareholder meeting	Notice of Postal Ballot
2026-07-03	Board meeting outcome	Outcome of Board Meeting held on July 03, 2026.
2026-06-17	Change in Auditors	Change in Auditors of the company.
2026-06-16	General Updates	General Updates. (Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Resignation and Appoint...
2026-06-16	Board meeting outcome	Outcome of Board Meeting held on Jun 16, 2026. (Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, ...
2026-06-16	Change in Auditors	Change in Auditors of the company.
2026-05-29	Integrated Filing- Financial	Integrated Filling_Finacial Results for the year 31-03-2026
2026-05-29	Board meeting outcome	Indo Us Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-04-30	General Updates	Confirmation regarding not falling under the Large Corporate Criteria with reference to SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 2...
2026-04-22	Resignation	Resignation of Mrs Neha Sachinbhai Patel as Non- Executive Independent Director of the company w.e.f. April 21, 2026. Revised Announcement under Reg 3...
2026-04-22	Director change	Change in Director(s) of the company.

Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.

No short selling reported to NSE in our files.

Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.

Less than 100 unique PAN traded in previous 30 days

Quick answers

What is the market cap of Indo US Bio-Tech Ltd?

Indo US Bio-Tech Ltd (INDOUS) has a market capitalisation of Rs 156 Cr. at the 2026-10-01 close.

What is the P/E ratio of Indo US Bio-Tech Ltd?

Indo US Bio-Tech Ltd trades at a P/E of 13.6 on trailing twelve-month profit, at the 2026-10-01 close.

What were Indo US Bio-Tech Ltd's latest quarterly results?

In the Jun 2026 quarter, Indo US Bio-Tech Ltd sales was Rs 33 Cr (+7.2% vs Jun 2025) and net profit was Rs 3 Cr.

What is the 52-week high and low of Indo US Bio-Tech Ltd?

The 52-week high is Rs 159.00 and the 52-week low is Rs 70.00.